CD-CAPITAL
30.11.2022 11:05:38 CET | Business Wire | Press release
CD Capital is thrilled to announce Carmel Daniele’s successful nomination in 2022’s edition of “100 Global Inspirational Women in Mining” (WIM100), a biennial publication that celebrates the “above & beyond” contributions of women to the mining industry, across all roles, seniority and jurisdictions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221129005553/en/
Carmel Daniele nominated in 2022's WIM100 (Photo: Business Wire)
CD Capital is proud that Ms Daniele has received this recognition for her pioneering work within the mining private equity sector. Ms Daniele, CD Capital’s Founder and Chief Investment Officer commented,
“I feel both honoured and humbled to have been nominated for this prestigious award to stand alongside many other pioneering women in our field. By working together, we make a powerful force in creating positive change for the future and inspiring other women to join our sector that is key to the greening of our planet for generations to come”.
Ms Daniele is a leader in her field, having established CD Capital in 2006, being one of the first in London to set up a dedicated fund focused on private mining assets and winning a prestigious mining finance industry award in 2008. She has since launched two further natural resource funds and has raised c.$1bn in capital from leading institutional investors. CD Capital’s global portfolio invests in the development of projects that will supply critical minerals for the green transition, as well as the key ingredients used in fertilisers to ensure food security for the world. Projects are primarily in jurisdictions that can rely on their own abundance of green energy, such as Latin America, Canada, Australia and Europe.
Since establishing CD Capital, Ms Daniele has built a world-class investment technical team of industry insiders. Ms Daniele also actively sponsors women studying Geology at Imperial College through its internship and mentoring programme.
The 100 Global Inspirational Women in Mining 2022 publication includes more on WIM100 on page 3 and features Ms Daniele on page 47. In 2022, WIM 100 received 915 nominations for 491 women in mining from 61 countries.
These 100 inspirational women have been chosen using the following selection criteria:
1. She is a trailblazer: A WIM100 woman is a pioneer. She is an innovator. She makes positive and impactful changes so the industry can operate in a more sustainable, inclusive and safer way.
2. She advocates and empowers: A WIM100 woman offers proactive advocacy to those working in the mining industry and beyond. She empowers her colleagues to ensure everyone feels heard, welcomed and respected.
3. She perseveres in the face of adversity: A WIM100 woman is resilient and determined. She has the courage to speak up, challenge the status quo and break barriers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221129005553/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
